Navigation Links
Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed
Date:1/8/2009

CAMBRIDGE, Mass. and COLUMBUS, Ohio, Jan. 8 /PRNewswire/ --IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that verification studies of the IntelligentMDx BK Viral Quantitative Assay are complete.

Under the verification protocol the Limit of Detection, linearity, specificity and reproducibility and robustness of the BK Viral Quantitative Assay were determined. The data obtain agreed with internally generated analytical performance data generated at IntelligentMDx. The data was consistent with data obtained from external clinical data obtained from Washington University that was presented at the 14th Annual Meeting of the Association for Molecular Pathology. The verification studies were performed at Battelle.

Based upon the data obtained the assay was shown to have a Limit of Detection of 8 copies of BK target per assay. The assay was linear over the 5 log range that was tested having an R-squared value is 0.99; this calculates to an amplification efficiency of 94.5%. In addition the specificity (false negative rate) for the assay was shown to be 100% for the limited number of true negatives assessed. Precision and robustness testing showed that the test was highly precise and robust with inconsequential variation observed in day-to-day and tech-to-tech testing. Analysis of the standard quantitative curves for each plate run (n=14) showed an average slope is -3.37 with a 95 percent confidence interval of (-3.47, -3.27) with all R-squared values are above 0.99 with the exception of one plate.

About IntelligentMDx

IntelligentMDx's mission is to make FDA approved diagnostic kits. To guarantee quality for customers and partners we design, develop and manufacture tests under FDA Quality System Regulations and ISO 13485:2003 guidelines. These tests have been, and will be, designed to run on a broad range of molecular systems for c
'/>"/>

SOURCE IntelligentMDx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
4. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
5. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
6. Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder
7. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
10. Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting
11. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...v. 20 Cornerstone Therap...utical company focused on acquiring, developing an...or the respiratory and related markets, today repo...e Food and Drug Administration ("FDA") alleging th... HCl 10 mg, Pyrilamine Maleate 16 mg) and Deconsal...
(Date:11/20/2009)... Nov. 20 /PRNewswire-FirstCall/ -- Landauer, In...he fiscal fourth quarter and full year of 2009 pre...mpany will host a conference call for investors on...ime. Investors may access the live call by dialing...), or 480-629-9835 (international callers), or by ...
(Date:11/20/2009)...a., Nov. 20 The Departm...shots to members of priority groups that did not h...of 18 clinics are being held statewide on Nov. 20-.... Hours on Saturday, Nov. 21, will be 8 a.m. to 2 ...from 2 p.m. to 8 p.m. ,, Individuals in the re...
Breaking Medicine Technology:Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results 2Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2HealthyFeetStore com Celebrates 5th Anniversary 61506 1HealthyFeetStore com Celebrates 5th Anniversary 61506 2New HIMSS Analytics Survey Reveals Healthcare Business Associates Are Unprepared for Data Breach 61502 1New HIMSS Analytics Survey Reveals Healthcare Business Associates Are Unprepared for Data Breach 61502 2New HIMSS Analytics Survey Reveals Healthcare Business Associates Are Unprepared for Data Breach 61502 3Vivakor Inc Announces Stock Dividend 14870 1Vivakor Inc Announces Stock Dividend 14870 2Vivakor Inc Announces Stock Dividend 14870 3Vivakor Inc Announces Stock Dividend 14870 4
...(Nasdaq:,DNDN) will host a conference call today, ... to review the outcome of the interim analysis of ...oma Treatment, also known as D9902B),clinical tria...estigational,active cellular immunotherapy for the...interested may access the call with the following ...
...ewest study site, PHILADELPHIA, Oct. 3 The Child...ntract to manage a new study site in The,National ...local,participation, recruitment and data collecti...funded by the National Institutes of Health., Inv... in Burlington,County will participate in the stud...
Other Medicine Technology:Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2
(Date:11/22/2009)... , , WASHINGTON, Nov. 21 /PRNewswire-USNews...e following statement upon the United States Senat...e Health Care legislation: ,, "Senators Arlen S...lphians and all Pennsylvanians for casting stand-u...President Obama,s historic Affordable Health Care ...
(Date:11/21/2009)... , , WASHINGTON, Nov. 21 /PRNewswire-USN...1990s to eliminate onchocerciasis (river blindness...evalence of the disease in recent years, as eviden... requiring mass drug administration in six endemic...th annual meeting of the American Society of Tropi...
(Date:11/21/2009)... , HAPPYneuron,s most pop...ble on the iPhone and iPod Touch. , ...2009 -- HAPPYneuron,s most popular and addictive g...d iPod Touch. Split Words is designed to help bani...,The SplitWords iPhone brain game challenges the...
(Date:11/20/2009)... , , PRINCETON, NJ, Nov. 20 /PRNewswire-F...d today that a Special Meeting of Shareholders wil...e of the Meeting is to consider approval of two sp... to approve and authorize the sale of all or subst...ly on the terms provided for in the asset purchase...
(Date:11/20/2009)... , , MADISON, N.J., Nov. 20 /PRNewswire... influenza virus may have peaked in late October, ...tial source of illness in all age groups, includin...Diagnostics Incorporated (NYSE: DGX ), the world...tion and services. ,, In its most recent Quest...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...lligence could be defined as the capacity to perce...d those of others so as to be able to distinguish ...de for one,s thoughts and actions. One of the impo...tural world more effectively. , The Stress and He...
...side-Naive Chronic Hepatitis B e-Antigen (HBeAg) ...d One Patient with Genotypic Resi...ers Squibb Company,(NYSE: BMY ) today announced d...e amount of hepatitis B virus in the,blood, or vir...
...lar Instruments, Inc.,developer and manufacturer o...ressure-volume (P-V) systems, today announced the ...mall and large animal models. The MPVS Ultra simu... transgenic mice to domestic livestock. Using,the ...
..., Inc. (Nasdaq:,CRYO), a medical device company fo...ounced today the appointment of Mark Adams as Vice...s to CryoCor over 20 years,of cardiac related medi... which was approved by the FDA in August 2007,for ...
...Corporation (Nasdaq:,DNDN) will release its third ... 2007. Company management will host a conference c...ial results and provide a general,corporate update...tic) or +1-719-325-4876 (international) Webcast: ...
...2 Progen,Pharmaceuticals Limited (ASX: PGL; Nasda...nt Fast Track designation awarded to PI-88 for the...e resection of primary,liver cancer and in order t...has used the Special Protocol Assessment (SPA) pro...
Other Medicine News:Health News:Emotional Intelligence and the use of tobacco and cannabis 2Health News:Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels 2Health News:Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels 3Health News:Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels 4Health News:Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels 5Health News:Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels 6Health News:Millar Instruments Launches Complete Pressure-Volume System for Large and Small Animal Models 2Health News:CryoCor Appoints New Vice President of Sales and Marketing 2Health News:CryoCor Appoints New Vice President of Sales and Marketing 3Health News:CryoCor Appoints New Vice President of Sales and Marketing 4Health News:-Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET- 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 2Health News:Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer 3
1.0mm Trephine with Handle
3.5mm Trephine with Handle
8.0mm Calibrated Trephine Handle
7.25mm Calibrated Trephine Handle
Medicine Products: